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Background: Protein arginine methyltransferase 6 (PRMT6) can methylate the HIV-1 Tat, Rev and nucleocapsid
proteins in a manner that diminishes each of their functions in in vitro assays, and increases the stability of Tat in
human cells. In this study, we explored the relationship between PRMT6 and HIV-1 Tat by determining the domains
in each protein required for interaction.
Methods: Through domain mapping and immunoprecipitation experiments, we determined that both the amino
and carboxyl termini of PRMT6, and the activation domain within Tat are essential for interaction. Mutation of the
basic domain of Tat did not affect the ability of PRMT6 to interact with Tat.
Results: We next used the A549 human alveolar adenocarcinoma cell line, which naturally expresses undetectable
levels of PRMT6, as a model for testing the effects of PRMT6 on Tat stability, transactivation, and HIV-1 replication.
As previously observed, steady state levels and the protein half-life of Tat were increased by the ectopic expression
of PRMT6. However, no down regulation of Tat transactivation function was observed, even with over 300-fold
molar excess of PRMT6 plasmid. We also observed no negative effect on HIV-1 infectivity when A549 producer cells
overexpressed PRMT6.
Conclusions: We show that PRMT6 requires the activation domain, but surprisingly not the basic domain, of Tat for
protein interaction. This interaction between Tat and PRMT6 may impact upon pathogenic effects attributed to Tat
during HIV-1 infection other than its function during transactivation.
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The HIV-1 Tat protein is a transcriptional activator that
plays an essential role during the late phase of viral rep-
lication. Its primary function is to significantly enhance
proviral gene expression so that HIV-1 RNA and pro-
teins may be produced for later assembly into infectious
virion particles. Tat is recruited along with positive tran-
scription elongation factor b (P-TEFb), primarily com-
posed of cyclin T1 and CDK9, to the RNA polymerase II
pre-initiation complex (PIC) assembled at the proviral
start site of transcription [1]. Localization of Tat and
P-TEFb to the PIC is achieved by the association of P-
TEFb, initially complexed with a 7SK small nuclear* Correspondence: david.harrich@qimr.edu.au
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distribution, and reproduction in any mediumribonucleoprotein (snRNP) particle [2], with the start
site of transcription, and by the coordinated binding of
Tat and cyclin T1 to the transactivation response elem-
ent (TAR) RNA stem-loop structure. TAR is spontan-
eously formed from the nascent mRNA transcribed by
RNA polymerase II during transcriptional initiation. The
basic domain of Tat is implicated in binding to TAR,
whereas the amino-terminal activation domain of Tat in-
teracts with cyclin T1 [1]. The coordinated binding of
Tat and cyclin T1 to TAR enables the release of P-TEFb
from the 7SK snRNP particle, the hyperphosphorylation
of RNA polymerase II by CDK9, the alleviation of negative
elongation factors that arrest the polymerase, and the effi-
cient processivity of transcriptional elongation [3,4].
Tat is posttranslationally modified by host factors shortly
before or during transactivation [5]. One class of Tat
modification that is of emerging interest is methylation atntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 The termini of PRMT6 are required for the interaction
with HIV-1 Tat. (A) Upper panel, scale representation of PRMT6
protein showing amino acid positions 1 and 375, the catalytic
domain (gray), and the signature methyltransferase motifs (I, I0, II and
III; black bars). Lower panel, scale representations of Myc epitope-
tagged PRMT6 (Myc-PRMT6) protein and derivative domain deletion
mutants. The numbers above each schema represent the amino
acid boundaries of the domain deletions. The amino-terminal Myc
epitope tag is represented as a vertical bar. (B) Interactions between
FLAG epitope-tagged Tat (Tat-FLAG) and wild type or domain
deleted Myc-PRMT6 as determined by immunoprecipitation. HeLa
cells were transfected to express Tat-FLAG with either wild type
Myc-PRMT6 (WT) or a domain deletion mutant of Myc-PRMT6.
Immunoprecipitations were performed on lysates prepared from
transfected cells using anti-FLAG agarose beads (αFLAG IP). Cell
lysates (left panel) and immunoprecipitates (right panel) were
western blotted using anti-Myc and anti-FLAG antibodies. Loading
of cell lysates was normalized for equal amounts of co expressed
Renilla luciferase in each sample. The Myc-PRMT6 domain deletion
mutant designations are as in A. Data are representative of three
independent experiments.
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ylated within its basic domain by protein arginine methy-
ltransferase 6 (PRMT6) [7], SETDB1, SETDB2 [8] and
Set7/9-KMT7 [9], and can be demethylated by LSD1/
KDM1 following methylation of lysine-51 [10]. Most post-
translational modifications of Tat appear to have stimula-
tory effects on Tat transactivation [11]. In contrast, PRMT6
has been shown to down regulate transactivation by a
proposed mechanism in which methylation of Tat arginine-
52 interferes with the interaction with TAR [7,12], even
though overexpression of PRMT6 results in the increased
stability of Tat through inhibition of proteasome-dependent
degradation [13]. PRMT6 is a type I enzyme of the protein
arginine methyltransferase family [14] which, among other
functions, regulates cellular gene expression by methy-
lating arginine-2 of histone H3. Deposition of a methyl
group at arginine-2 interferes with the trimethylation of
lysine-4 in histone H3, a post-translational modification
associated with chromatin remodeling amiable to gene
expression [15-18].
In addition to Tat, PRMT6 was also discovered to
methylate the HIV-1 Rev [19] and nucleocapsid pro-
teins [20], again within their respective RNA binding
domains and in a manner which down regulates func-
tion. Overexpression of PRMT6, however, does not
affect the stability of Rev [13]. This apparent targeting
of three viral proteins by a single host factor has led to
the hypothesis that PRMT6 is a HIV-1 restriction factor
[7]. In this study, we aimed to firstly explore the rela-
tionship between Tat and PRMT6 by mapping the do-
mains of interaction within both proteins, and secondly
to develop a robust cellular model for further testing
the effects of PRMT6 on HIV-1 replication. We show
that the amino and carboxyl termini of PRMT6 are re-
quired for interaction and that, unexpectedly, the acti-
vation domain but not the basic domain is the site of
interaction within Tat. We also demonstrate that the
A549 cell line expresses PRMT6 protein at a level un-
detectable by western blot. Utilizing the A549 cell line
in models of Tat transactivation and HIV-1 infectivity,
we show that overexpression of PRMT6 does not down
regulate either transactivation or infectivity, in contrast
to previously published results [7,12]. Our data invite
the re-examination of the role of PRMT6 during HIV-1
replication and suggest that further evidence is re-
quired before PRMT6 can definitively be considered a
restriction factor.
Results
The termini of PRMT6 interact with Tat
Little is known about the functional domains of PRMT6
apart from a catalytic methyltransferase domain that is
conserved among all members of the protein arginine
methyltransferase family [14,21]. We and others havepreviously demonstrated that PRMT6 functionally inter-
acts with the HIV-1 Tat protein [7,12,13]. It is not known,
however, which region of PRMT6 is required for this
interaction. Therefore, to map the region of PRMT6 that
interacts with Tat, we created several “domain” deletion
mutants in a plasmid expressing MYC epitope tagged-
PRMT6 (Myc-PRMT6) in a manner that encompassed the
entire length of the PRMT6 protein (Figure 1A). The
panel of mutants created included a deletion of the amino
terminal region adjacent to the catalytic domain (ΔN), a
deletion of the catalytic domain itself (ΔCD), and deletions
of three non-overlapping regions at the carboxyl end
(ΔC1, ΔC2 and ΔC3; Figure 1A).
AB
Figure 2 The activation domain of Tat is required for the
interaction with PRMT6. (A) Upper panel, scale representation of
the two exon-encoded HIV-1 Tat protein showing amino acid
positions 1 and 101, functional domains (italicized text) and
structural regions (bold text) as defined by [22]. ARM, arginine rich
motif; Aux., auxiliary region. Lower panel, scale representations of
FLAG epitope-tagged Tat (Tat-FLAG) protein and derivative domain
deletion mutants. The numbers above each schema represent the
amino acid boundaries of the domain deletions. The carboxyl-
terminal FLAG epitope tag is represented as a vertical bar. (B)
Interactions between Myc epitope-tagged PRMT6 (Myc-PRMT6) and
wild type or domain deleted Tat-FLAG as determined by
immunoprecipitation. HeLa cells were transfected to express
Myc-PRMT6 with either wild type Tat-FLAG (WT) or a domain
deletion mutant of Tat-FLAG. Immunoprecipitations were performed
on lysates prepared from transfected cells using anti-FLAG agarose
beads (αFLAG IP). Cell lysates (left panel) and immunoprecipitates
(right panel) were western blotted using anti-Myc and anti-FLAG
antibodies. Loading of cell lysates was normalized for equal amounts
of co expressed Renilla luciferase in each sample. The Tat-FLAG
domain deletion mutant designations are as in A. Data are
representative of three independent experiments.
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Tat, immunoprecipitations were performed with lysates
from HeLa cells co expressing FLAG epitope-tagged Tat
(Tat-FLAG) and either wild-type Myc-PRMT6 or one of
the domain deletion mutants. Surprisingly, the immuno-
precipitation of Tat-FLAG revealed that the catalytic
domain mutant of Myc-PRMT6 (ΔCD) was robustly co-
immunoprecipitated (Figure 1B, lane ΔCD). This indi-
cates that the catalytic domain, which is responsible for
Tat methylation [7], is nonetheless dispensable for the
interaction between PRMT6 and Tat. Similarly, the Myc-
PRMT6 ΔC1 and ΔC2 mutants interacted with Tat-FLAG
to a similar degree to wild-type Myc-PRMT6 (Figure 1B,
lanes WT, ΔC1 and ΔC2). In contrast, neither the Myc-
PRMT6 ΔN mutant nor the ΔC3 mutant could be effi-
ciently co-immunoprecipitated in repeated experiments
(Figure 1B, lanes ΔN and ΔC3), demonstrating that these
regions are required for Tat interaction. The data therefore
show that the termini of PRMT6, and not its catalytic do-
main, are the mediators of interaction with HIV-1 Tat.
The activation domain of Tat interacts with PRMT6
PRMT6 methylates Tat within its basic domain, also
known as the arginine rich motif [7,12,13]. To determine
if the basic domain is required and sufficient for the
interaction between Tat and PRMT6, we similarly cre-
ated domain deletion mutants in the plasmid expressing
Tat-FLAG. Since the functional domains of Tat are well
characterized [22], we thus created a panel of mutants
(Figure 2A) that included two non-overlapping deletions
of the activation domain (Δ16, ΔCC), a deletion of the
basic domain (ΔB) and a deletion of the domain encoded
by the tat second exon (ΔSE).
Immunoprecipitations were perform with lysates
from HeLa cells co expressing wild-type Myc-PRMT6
and either wild-type Tat-FLAG or one of the domain
deletion mutants. Unexpectedly, immunoprecipitation
of the Tat-FLAG basic domain deletion mutant detect-
ably co-immunoprecipitated Myc-PRMT6 (Figure 2B,
lane ΔB). The result clearly indicates that the basic do-
main of Tat is not absolutely critical for the interaction
with PRMT6. The Tat-FLAG ΔSE mutant similarly
interacted with Myc-PRMT6 (Figure 2B, lane ΔSE). In
contrast, deletions made to the activation domain of Tat
resulted in somewhat reduced (in the case of the Δ16 mu-
tant) or abrogated (ΔCC mutant) interaction with Myc-
PRMT6 (Figure 2B, lanes Δ16 and ΔCC). The data there-
fore suggest that the Tat activation domain, and not the
basic domain, is the important mediator of interaction
with PRMT6.
To confirm the results revealed by the domain dele-
tion mutants, we repeated the immunoprecipitation ex-
periment with Tat-FLAG mutants in which amino acid
substitutions were introduced into the activation andbasic domains. Three Tat-FLAG mutants were created
(Figure 3A), one in which amino acids Glu-2, Asp-5 and
Glu-9 were mutated to alanine residues (EDE mutant), an-
other in which all the cysteine residues between amino
acids 21 to 38 were mutated to serine residues (CS mu-
tant), and one in which all the amino acids within the
basic domain were mutated to glycine or alanine residues
(NB mutant). Immunoprecipitations of the Tat-FLAG
mutants in lysates from HeLa cells co expressing Myc-
PRMT6 revealed that the EDE mutant could not efficiently
interact with Myc-PRMT6 (Figure 3B), whereas the NB
mutant remained able to interact (Figure 3C). Expression
of the CS mutant in cell lysate samples was less than wild
AB
C
Figure 3 Acidic and cysteine residues within the Tat activation domain are required for interaction with PRMT6. (A) Schematic
representation of the Tat activation domain from amino acids 1 to 37 and the basic domain from amino acids 49 to 57. The wild type (WT)
amino acid sequence is shown using the single-letter amino acid code. Sequences of the acidic residues mutant (EDE), the cysteine residues
mutant (CS) and the basic domain mutant (NB) are also shown, with substitution mutations indicated in reverse video. ARM, arginine rich motif.
(B) Interactions between Myc epitope-tagged PRMT6 (Myc-PRMT6) and wild type, EDE mutant or CS mutant FLAG epitope-tagged Tat (Tat-FLAG)
as determined by immunoprecipitation. HeLa cells were transfected to express Myc-PRMT6 with either wild type Tat-FLAG (WT) or one of its
mutants as indicated. Immunoprecipitations were performed on lysates prepared from transfected cells using anti-FLAG agarose beads (αFLAG
IP). Cell lysates (left panel) and immunoprecipitates (right panel) were western blotted using anti-Myc and anti-FLAG antibodies. (C) The same
experiment as in B was performed with the NB mutant of Tat-FLAG. Loading of cell lysates was normalized for equal amounts of co expressed
Renilla luciferase in each sample. All data are representative of three independent experiments.
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on Tat interaction with PRMT6 remains to be conclusively
determined. The amino acids mutated within the activa-
tion domain of the EDE mutant have been previously
shown to be important for the transactivation function of
Tat [23-25]. It is thus demonstrated that key amino acid
residues within the activation domain of Tat are necessary
not only for transactivation, but also for the interaction
between Tat and PRMT6.
The A549 cell line naturally expresses low levels of
PRMT6
Previous investigations of the effects of PRMT6 on HIV-
1 replication have involved the use of cell lines thatrobustly express endogenous levels of PRMT6 protein
[12,13,19,20]. Consequently, the degree of influence of
this endogenous population of PRMT6 on investigations
requiring the transfection of ectopic PRMT6 is unknown.
We reasoned that human cell lines that naturally express
no or low levels of PRMT6 might make ideal models for
exploring the host-pathogen relationship between PRMT6
and HIV-1. To this end, we interrogated the UniGene
expressed sequence tag (EST) profile database [26] for
candidate tissue types in which PRMT6 ESTs were infre-
quently reported. When classified by health state, lung
tumor and lymphoma tissue were reported to have zero
transcripts per million (TPM) of PRMT6 transcripts, com-
pared to 87 TPM for cervical tumor tissue and 58 TPM
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lung tissue was reported to express 14 TPM of PRMT6
transcripts compared to 61 TPM for normal cervical tissue
and 47 TPM for normal kidney tissue (Table 1). In contrast,
both lung tumor and lymphoma tissue express higher levels
of protein arginine methyltransferase 1 (PRMT1), a rela-
tively abundant methyltransferase [14], at 300 and 432
TPM respectively (Table 1).
Guided by the PRMT6 EST data, we therefore obtained
human cell lines derived from lung tumor and lymphoma
tissue. We chose the A549 human cell line [27], derived
from an adenocarcinoma of alveolar basal epithelium ori-
gin, and the BJAB human lymphoblastoid cell line [28],
derived from an Epstein-Barr virus-negative Burkitt’s
lymphoma, respectively. Western blotting for PRMT6
showed that A549 cells had undetectable levels of the
protein, in contrast to BJAB and HeLa cells, while all three
cell lines had readily detectable PRMT1 protein (Figure 4A).
Relative quantification by reverse transcription poly-
merase chain reaction (PCR) revealed a 5.9-fold deficit
of PRMT6 mRNA transcripts in A549 cells when com-
pared to HeLa cells (Figure 4B). This was determined
using Pfaffl’s method of mRNA quantification [29], in
which the relative expression ratio of PRMT6 tran-
scripts between A549 and HeLa cells was normalized to
the expression of GAPDH transcripts. In contrast, a
similar determination of PRMT1 mRNA levels revealed
only a 1.8-fold difference between A549 and HeLa cells
(Figure 4B). We therefore demonstrate that the A549 cell
line naturally expresses undetectable levels of PRMT6 pro-
tein due to a dearth of PRMT6 mRNA.
When we transfected A549 cells to express Tat-FLAG
(250 ng of plasmid) with or without Myc-PRMT6 (250 ng
of plasmid), we observed a strong increase in Tat-FLAG
protein steady-state levels in the presence of Myc-PRMT6
(Figure 4C). We have previously demonstrated that
catalytically-active PRMT6 can increase the protein half-Table 1 Expressed sequence tag data (shown as
transcripts per million) for the PRMT6 and PRMT1 genes




Cervical tumor 87 174
Kidney tumor 58 145





Lung 14 179life of Tat in HeLa cells in a manner dependent on argin-
ine methylation [13]. We therefore aimed to determine if
a similar phenomenon was observable in A549 cells,
which would indicate that ectopically-expressed PRMT6 is
biologically active in the A549 cell line. Cells transfected
to express Tat-FLAG (1 μg of plasmid) with or without
coexpressing Myc-PRMT6 (1 μg of plasmid) were treated
with cycloheximide (CHX) in order to arrest protein trans-
lation. At various time points post-treatment, transfected
cells were harvested and assayed by western blot for Tat-
FLAG, Myc-PRMT6 and endogenous β-tubulin expression.
As similarly observed in Figure 4C, co expression of Myc-
PRMT6 greatly enhanced the steady-state levels of Tat-
FLAG just prior to CHX treatment (0 h time point), levels
that were sustained by Myc-PRMT6 over the time course
(Figure 4D). In contrast, Tat-FLAG levels in the absence of
Myc-PRMT6 co expression quickly reduced to undetect-
able levels (Figure 4D). Endogenous β-tubulin protein levels
remained stable throughout the time course. A plot of the
Tat-FLAG band intensities over time enables calculation of
Tat-FLAG protein half-lives in either the presence or ab-
sence of Myc-PRMT6 [13]. Such a calculation revealed that
Myc-PRMT6 increased the protein half-life of Tat-FLAG
by 5.6-fold (from 3.5 h to 19.5 h; Figure 4E). This suggested
that ectopically-expressed PRMT6 can robustly increase
Tat protein stability in A549 cells, thereby confirming that
Myc-PRMT6 is biologically effective in A549 cells.
PRMT6 does not down regulate HIV-1 gene expression in
A549 cells
We used the A549 cell line to confirm the hypothesis that
overexpression of PRMT6 down regulates Tat transactiva-
tion function. We firstly overexpressed Myc-PRMT6 in
A549 cells cotransfected with a Photinus luciferase reporter
plasmid containing the long terminal repeat (LTR), the
HIV-1 promoter. This allowed us to test the effect of
PRMT6 on basal transcription. When normalized for con-
stitutive Renilla luciferase expressed from a SV40 promoter,
we observed no change in basal transcription from the LTR
in the presence of either 50 ng (p = 0.96, two-tailed Stu-
dent’s t test) or 250 ng of Myc-PRMT6 plasmid (p = 0.30;
two-tailed Student’s t test) compared to the no Myc-
PRMT6 control (Figure 5). Next we tested the effect of
PRMT6 on Tat-mediated transactivation of the LTR. Previ-
ous studies have employed HEK293T (human embryonic
kidney) [7] or HeLa cells [12] to test this hypothesis, using
100 ng of Tat expression plasmid along with 0.5 μg or 1 μg
of PRMT6 expression plasmid [7] or between 0.05 μg and
0.5 μg of PRMT6 plasmid [12]. In contrast, we transfected
A549 cells with 0.15 ng and 0.5 ng of Tat-FLAG expression
plasmid either with or without 50 ng of the wild type Myc-
PRMT6 plasmid. This represents either a 333-fold or 100-
fold molar excess of Myc-PRMT6 plasmid compared to




Figure 4 The A549 cell line does not express detectable levels of PRMT6 protein. (A) Western blot of cell lysates from the A549, BJAB and
HeLa cell lines detected with anti-PRMT6, anti-PRMT1 and anti-β-tubulin antibodies as indicated. (B) Relative expression ratios of PRMT1 and
PRMT6 mRNA transcripts in A549 versus HeLa cells. Total RNA were extracted from A549 and HeLa cells before being reverse transcribed into
cDNA using random primers. Quantitative PCR was then performed on the cDNA samples using primers specific for PRMT1, PRMT6 and GAPDH
transcripts. Relative expression ratios for PRMT1 and PRMT6 were calculated according to the method of [29]. (C) Ectopic Myc-PRMT6 increases the
steady state levels of Tat-FLAG protein in A549 cells. Western blotting was performed on A549 cells transfected to express Tat-FLAG with (+) or
without (−) Myc-PRMT6. Proteins were detected with anti-FLAG and anti-PRMT6 antibodies, respectively. Loading of cell lysates was normalized
for equal amounts of co expressed Renilla luciferase in each sample. (D) A549 cells transfected to express Tat-FLAG with or without Myc-PRMT6
were treated with cycloheximide and harvested at 0, 1, 2, 4, 6 and 8 h post-treatment. Western blotting was performed on total protein-equalized
lysates. β-tubulin levels demonstrate equal sample loadings. (E) The Tat-FLAG band intensities in panel D were quantified, and their natural log
values were plotted as a function of time. Values for Tat-FLAG co expressed with Myc-PRMT6 are indicated by the black boxes and values for
Tat-FLAG expressed alone by the white boxes. The calculated Tat-FLAG protein half-lives are shown in the inset.
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affect its functions [7,12,13,19,20,30,31]. We cotransfected
cells with the LTR-Photinus luciferase reporter to indicate
the effects of PRMT6 on Tat transactivation, and the SV40
promoter-Renilla luciferase plasmid to control for varia-
tions in transfection efficiencies and to gauge non-specific
effects on plasmid expression.When normalized for Renilla luciferase expression, we
saw no evidence in A549 cells of PRMT6-mediated down
regulation of Tat transactivation with either 0.15 ng of
Tat-FLAG plasmid (p = 0.39, one-tailed Student’s t test) or
0.5 ng of Tat-FLAG plasmid (p = 0.27, one-tailed Student’s
t test; Figure 6A). To discount cell line-specific influences
on the results, we repeated the experiment in HeLa cells.
Figure 5 Overexpression of Myc-PRMT6 does not affect basal
transcription from the HIV-1 LTR promoter. A549 cells were
transfected with a long terminal repeat (LTR)-Photinus luciferase
transcriptional reporter plasmid with varying amounts of Myc-PRMT6
plasmid, as indicated. All samples were cotransfected with a
SV40-promotered Renilla luciferase plasmid to control for
transfection efficiency variations. Transfected cells were lysed and
assayed for both Photinus and Renilla luciferase activities, the ratio of
which is shown for each sample. Columns represent the means and
standard deviations of three independent experiments.
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of normalized transactivation in HeLa cells with either
0.15 ng or 0.5 ng of Tat-FLAG plasmid (p = 0.35 and p =
0.34, respectively, one-tailed Student’s t test; Figure 6B).
Importantly, there were no statistically significant differ-
ences in total-protein normalized Renilla luciferase ex-
pression between samples in either the A549 (Figure 6C)
or HeLa (Figure 6D) cell lines (p > 0.05, two-tailed Welch’s
t test), indicating that the various plasmids transfected in
each experiment did not adversely affect overall expres-
sion levels. We therefore found, in contrast to previously
published results [12], that PRMT6 has no statistically sig-
nificant effects on Tat-mediated transactivation in either
A549 or HeLa cells.
HIV-1 produced in A549 cells overexpressing PRMT6 are
competent for infection
The prevailing hypothesis is that PRMT6 is a negative regu-
lator of HIV-1 replication, targeting not only Tat [7,12], but
also the HIV-1 Rev [19] and nucleocapsid proteins [20].
We wanted to determine if PRMT6 overexpression will
affect HIV-1 infectivity in our A549 cell model. A549 cells
were transfected with either empty vector, wild type Myc-
PRMT6 plasmid or a plasmid expressing a mutant of Myc-
PRMT6 whose V86K and D88A amino acid substitutions
render it catalytically inactive [7]. These cells were cotran-
sfected with pGCH/EGFP, a proviral expression plasmid
which produces HIV-1 from a CMV immediate-early pro-
moter [13] and which contains the EGFP gene within the
nef coding region of the genome. The cells were alsocotransfected with a VSV-G plasmid to enable pseudo-
typing of virus particles. Expression of EGFP in target cells
inoculated with this pseudotyped virus indicates productive
infection.
After confirming expression of Myc-PRMT6 in the A549
virus producer cells (Figure 7A), both HeLa and A549 cells
were exposed to equal amounts of virus collected from the
producer cells and were subsequently quantified for EGFP
expression by flow cytometry (Figure 7B). When expressed
relative to the empty vector control, we saw no difference
in EGFP expression between the HeLa cells infected with
virus from the wild type Myc-PRMT6-expressing producer
cells and virus from the mutant Myc-PRMT6-express-
ing producer cells (p = 0.52, two-tailed Student’s t test;
Figure 7C). Similar results were observed when A549 cells
were used as target cells (p = 0.39, two-tailed Student’s t
test; Figure 7C). We therefore infer from the data that
overexpression of Myc-PRMT6 in A549 virus producer
cells has no impact on the subsequent infectivity of virus
thus produced.
Conclusions
The interaction between HIV-1 Tat and PRMT6
PRMT6 was described by Boulanger and co-workers as a
negative regulator of HIV-1 Tat transactivation [7]. The
mechanism of action they proposed involves PRMT6-
catalyzed methylation of Tat within its basic domain, which
subsequently disrupts formation of the Tat-TAR-cyclin T1
ternary structure critically required for activating trans-
cription at the HIV-1 proviral promoter [7,12]. Here we
provide further insight into this proposed mechanism by
demonstrating that the amino and carboxyl termini of
PRMT6 interact with the activation domain of Tat. We
show that the catalytic domain of PRMT6, while required
for Tat methylation [7] and Tat stabilization in cells [13],
is not required for interacting withTat (Figure 1). We also
demonstrate that the basic domain of Tat is dispensable
for the interaction with PRMT6 (Figure 2) despite being
the target domain of PRMT6-mediated methylation
[7,13]. Instead, it is the amino terminal of the Tat activa-
tion domain that is essential for binding to PRMT6
(Figure 3). However, the fact that the Tat-FLAG EDE mu-
tant could not interact with Myc-PRMT6 (Figure 3B), but
the Tat-FLAG Δ16 mutant could interact (Figure 2B),
suggests there may be a weaker interaction between the
Tat basic domain and PRMT6 (most likely during the ca-
talysis of Tat methylation) that is sterically hidden by the
Tat activation domain.
How both the amino and carboxyl ends of PRMT6
interact with Tat is currently unclear. Finding the solu-
tion to this problem, however, is confounded by a lack
of crystal structure data for PRMT6. Nonetheless, a crys-
tal structure has been resolved for rodent PRMT1 [32], a
highly conserved methyltransferase from the same family
A B
C D
Figure 6 Overexpression of Myc-PRMT6 does not alter Tat-FLAG mediated transactivation in either A549 or HeLa cells. (A) A549 cells
were transfected with a long terminal repeat (LTR)-Photinus luciferase transactivation reporter plasmid along with varying amounts of Tat-FLAG
plasmid, as indicated, and either with (black columns) or without (white columns) Myc-PRMT6 plasmid. All samples were cotransfected with a
SV40-promotered Renilla luciferase plasmid to control for transfection efficiency and assay variations. Transfected cells were lysed and assayed for
both Photinus and Renilla luciferase activities, the ratio of which is shown for each sample expressed relative to the “0 ng Tat-FLAG” sample.
Columns represent the means and standard deviations of four independent experiments. (B) The same experiment as in A was performed in
HeLa cells. Columns represent the means and standard deviations of three independent experiments. (C) Overexpression of PRMT6 does not alter
overall plasmid expression. The Renilla luciferase activities from A were normalized to total lysate protein concentrations before being expressed
relative to the “0 ng Tat-FLAG without Myc-PRMT6” sample. Samples in which Myc-PRMT6 plasmid was (+) or was not (−) cotransfected are
indicated. Columns represent the means and standard deviations of four independent experiments. (D) The same determinations as in C were
performed with the samples from B. Columns represent the means and standard deviations of three independent experiments.
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gests that the amino and carboxyl termini are in opposition
to each other on the same plane of the molecule [32]. If
the same arrangement is true for human PRMT6, then it is
plausible that both termini can simultaneously interact with
Tat. This would ascribe novel roles to these regions of
PRMT6, which have hitherto been functionally undefined.
The requirement for the Tat activation domain to me-
diate the interaction between Tat and PRMT6 is an intri-
guing discovery. The activation domain of Tat is critical
for binding to cyclin T1 as the Tat-TAR-cyclin T1 com-
plex assembles [1,33]. It is conceivable that binding of
PRMT6 to the Tat activation domain may occlude subse-
quent interactions between Tat and cyclin T1. As the
interaction between Tat and PRMT6 does not appear to
critically require the Tat basic domain (Figure 2), this oc-
clusion may occur either before or after the basic domainbinds to TAR during the initial phases of transactivation.
Recently, Sobhian and colleagues have shown that Tat can
assemble functionally distinct complexes in cells, one
which is transcriptionally active during HIV-1 transactiva-
tion (Tatcom1) and another which increases the available
pool of the P-TEFb transcription factor complex (Tatcom2)
[34]. Both of these assemblages require the binding of Tat
to cyclin T1 [34]. It is possible that PRMT6 may limit the
formation of such assemblages when bound to the Tat
activation domain. However, our data suggest this to be
unlikely. As neither basal transcription (Figure 5) nor Tat-
mediated gene expression (Figure 6) were inhibited by the
overexpression of PRMT6, it is likely that formation of a
Tat-pTEFb complex is more favorable over a Tat-PRMT6
interaction. Further experiments, including protein binding




Figure 7 HIV-1 produced in A549 cells overexpressing
Myc-PRMT6 are competent for infectivity. (A) A549 cells were
transfected with a HIV-1 proviral plasmid in which the EGFP gene
had been inserted into the nef reading frame, along with a plasmid
expressing the VSV-G envelope glycoprotein to enable
pseudotyping. Cells were simultaneously cotransfected with either
empty vector (−), the wild type Myc-PRMT6 plasmid (WT) or a
methyltransferase-inactive mutant Myc-PRMT6 plasmid (Mut.).
Western blotting was performed on producer cell lysates using an
anti-PRMT6 antibody. Loading of cell lysates was normalized for
equal amounts of co expressed Renilla luciferase in each sample.
(B) HeLa and A549 target cells were infected with the pseudotyped
viruses collected from the A549 producer cells in A after normalizing
for capsid levels. EGFP expression in the target cells, which indicates
successful infection, was then quantified by flow cytometry. A
representative dot plot of target cells infected with virus from the
empty vector-cotransfected producer cells is shown, in which
GFP-positive, phycoerythrin (PE)-negative cells are gated (green).
(C) The proportions of GFP-positive HeLa (black columns) and A549
(white columns) target cells were quantified for each infection
sample and are shown arranged by the Myc-PRMT6 plasmid
cotransfected in the virus producer cells. Data are expressed relative
to the respective empty vector sample (“None”), and columns
represent the means and standard deviations of two independent
infections using independent virus stocks.
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The role of PRMT6 in HIV-1 biology is worthy of investiga-
tion, as at least three viral proteins have been demonstrated
to be directly methylated by this single methyltransferase
[7,19,20]. The need to develop new investigative tools and
models for PRMT6 function is therefore warranted. We
show here that the A549 human alveolar adenocarcinoma
cell line naturally expresses undetectable levels of PRMT6
protein (Figure 4A). The absence of PRMT6 detection was
attributed to the expression of low levels of PRMT6 mRNA
in the cell line (Figure 4B), corroborating data inferred from
the UniGene EST profile database (Table 1) [26]. We there-
fore believe that the A549 cell line can be used as a model
for studying the activities of PRMT6 on not only HIV, but
also on other pathogens [35] and on tumorigenesis [36].
Our experiments indicated that Myc-PRMT6 increases
steady-state levels of Tat-FLAG in A549 cells (Figure 4C),
and that catalytically-active Myc-PRMT6 increases the
protein half-life of Tat-FLAG (Figure 4D and 4E), as previ-
ously observed in HeLa cells [13]. Construing these data
as evidence for biological activity of ectopic PRMT6 in
A549 cells, we therefore used the A549 cell line to test
two aspects of the role of PRMT6 in HIV-1 replication.
Firstly, we tested the ability of PRMT6 to down regulate
Tat transactivation function [7,12]. Surprisingly, we dis-
covered that ectopically expressing PRMT6 in A549 cells
(in the form of catalytically active Myc-PRMT6) had no
statistically significant impact on Tat transactivation func-
tion using an LTR-luciferase reporter (Figure 6A). Import-
antly, we used very low amounts of Tat expression
plasmid in the experiments such that the molar ratio of
Myc-PRMT6 to Tat-FLAG was up to 333-fold, an amount
with which any effects of PRMT6 on Tat function should
have been readily observable. When we repeated the ex-
periments in HeLa cells, in which a negative effect of
PRMT6 on Tat function has been previously observed
[12], we again saw no statistically significant decrease in
Tat transactivation despite the 333-fold molar excess of
Myc-PRMT6 to Tat-FLAG (Figure 6B).
It is unclear why differing results were observed between
this study and that of Xie and colleagues [12]. One explan-
ation could be the amount of PRMT6 expression plasmid
used in the experiments. While we transfected 50 ng of
PRMT6 plasmid per 2-cm2 well in our experiments, Xie
and colleagues transfected up to 0.5 μg of PRMT6 plasmid
per 3.8-cm2 well. Endogenous PRMT6 is known to sup-
press gene transcription by regulating histone post-
translational modifications [15-18]. It is possible that
ectopic PRMT6 may do the same, so it is therefore im-
portant to control for changes in plasmid transcription
rates in experiments involving the transfection of PRMT6
expression plasmids. We observed no statistically signifi-
cant negative effects on transcription in our experiments
as determined with a SV40-promotered Renilla luciferase
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impact of PRMT6 transfection is unclear in the experi-
ments of Xie and co-workers. Another point of difference
is the clone of Tat used in the respective studies. While we
used 101-amino acid Tat derived from the BH10 clone of
HIV-1 (GenBank, accession number M15654), Xie and
colleagues used 101-amino acid Tat derived from the
HXB2 clone [37-39]. The amino acid sequences of these
two clones differ in the auxiliary and second exon do-
mains. It is possible that clonal differences of the Tat pro-
tein may account for the observed discrepancies between
the two studies.
Our second test in the A549 cell line model was to as-
sess the effect of PRMT6 on HIV-1 infectivity. This ap-
proach models the impact of PRMT6 on the viral Tat,
Rev and nucleocapsid proteins, all of which play import-
ant roles during the late phase of the HIV-1 life cycle.
We observed no differences in infectivity of HIV-1 pro-
duced in A549 cells cotransfected to express either an
empty vector, wild type Myc-PRMT6 or a catalytically-
inactive mutant of Myc-PRMT6 (Figure 7). In addition,
virus levels in the culture supernatants were similar in
all experiments (data not shown) suggesting that Rev,
which is required for structural protein synthesis, was
not inhibited. This contrasts with a study by Xie and
colleagues, where HIV-1 produced in HEK293T cells in
which PRMT6 was knocked down (by constitutively-
expressed siRNA) was found to replicate faster in target
cells within which PRMT6 was also constitutively knocked
down [12]. The target cells chosen in that study were of
the Jurkat lymphoblastoid cell line, a biologically more
relevant target compared to the HeLa cells used in this
study (Figure 7). However, it is important to note that the
molecular details of PRMT6’s impact on HIV-1 have all
been elucidated in HeLa or similar tissue culture lines
[12,13,19,20]. Furthermore, long-term stable knock down
of PRMT6 by RNA interference has an unknown effect on
general cellular gene expression, especially on those genes
whose expression is controlled by PRMT6-mediated me-
thylation of histones [16,17,31,36]. It is therefore difficult
to distinguish between direct (via viral proteins) and indir-
ect (via cellular gene expression) effects of PRMT6 knock
down on virus replication.
The data presented in this study prompt a revisit of the
hypothesis that PRMT6 is an anti-HIV restriction factor.
There is good evidence that PRMT6 can negatively influ-
ence HIV-1 replication [12], but neither its degree nor its
directness is completely known. In A549 cells, a cell line
that naturally expresses undetectable amounts of PRMT6
protein, there is little impact of PRMT6 overexpression
on Tat-mediated transactivation or viral infectivity. In con-
trast, in cells that robustly express PRMT6, within which
PRMT6 is constitutively knocked down by siRNA, there
appears to be a significant impact on HIV-1 replication[12]. Further work is needed to determine which has the
greater influence on HIV-1: the direct interactions be-
tween PRMT6 and viral proteins or the regulation of cel-
lular gene expression by PRMT6. While PRMT6 may
influence the pathogenic effects of Tat [40,41], we believe
that further evidence is required before PRMT6 can firmly
be considered a direct HIV-1 restriction factor.
Methods
Cell culture and transfections
The HeLa cell line was obtained from the ATCC biological
resource center (ATCC number CCL-2). The A549 alveolar
adenocarcinoma cell line [27] and the BJAB human
lymphoblastoid cell line [28] were gifts from Prof. Andreas
Suhrbier (Queensland Institute of Medical Research,
Brisbane, Australia). All cells were cultured in RPMI 1640
medium supplemented with 100 U ·ml-1 penicillin, 100 mg ·
ml-1 streptomycin and 10% [vol/vol] fetal bovine serum
(Sigma-Aldrich Corporation), and incubated at 37°C under
a humidified atmosphere of 5% CO2 in air. Transfections
were performed with X-tremeGENE HP transfection re-
agent (Roche Diagnostics Corporation) according to the
manufacturer’s instructions. Transfections were performed
in 6-cm dishes (28 cm2 dish surface area) for immunopre-
cipitation and protein translation arrest experiments, in 6-
well plates (9.6 cm2 well surface area) for western blotting,
and in 24-well plates (2 cm2 well surface area) for transacti-
vation assays.
Plasmids
The plasmid expressing the two-exon, 101 amino-acid,
BH10 clone of Tat fused to the FLAG epitope (pcDNA3.1/
Tat-FLAG) was a gift from Monsef Benkirane, Institut de
Génétique Humaine, Montpellier, France. The plasmids
expressing fusions between the Myc epitope tag and
wild type PRMT6 (pMyc-PRMT6) or methyltransferase-
deficient mutant PRMT6 (pMyc-PRMT6 mut) were gifts
from Stéphane Richard, McGill University, Montréal,
Canada. The mutant contains V86K and D88A amino acid
mutations compared to wild type PRMT6 (GenBank, ac-
cession number BC073866). The Myc-PRMT6 domain de-
letion mutants were created by inverse PCR using primers
as described in Table 2 and using pMyc-PRMT6 as tem-
plate. The Tat-FLAG domain deletion and substitution
mutants were similarly created by inverse PCR using
primers described in Table 2 and using pcDNA3.1/Tat-
FLAG as template. Creation of the NB mutant of Tat-
FLAG has been described elsewhere [42].
The Tat transactivation Photinus luciferase reporter
pGL3-LTR consists of the long terminal repeat from
HIV-1 clone SF2 inserted into pGL3-basic (Promega
Corporation) via Bam HI and Hind III restriction enzyme
sites. The LTR spans nucleotides −180 to +81, relative to
the start of transcription. The Renilla luciferase plasmid
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experiments where indicated. pGCH/EGFP was derived
from the pGCH proviral vector [13]. Firstly, the 3′ LTR re-
gion containing the nef open reading frame was subcloned
from pGCH to pUC19 via Bam HI and Xba I restriction
sites. Secondly, the nef start codon was mutated to an Age
I restriction site by inverse PCR before the EGFP gene
(Clontech Laboratories) was inserted via the Age I restric-
tion site and a pre-existing Xho I restriction site. Finally,
the EGFP-containing 3′ LTR was subcloned back into
pGCH via Bam HI and Xba I restriction sites. pCMV/
VSV-G, which expresses the vesicular stomatitis virus
envelope glycoprotein, was a kind gift from Assoc. Prof.
Ian Mackay (The University of Queensland, Brisbane,
Australia).Immunoprecipitations and western blot
For the immunoprecipitation experiments, HeLa cells in
6-cm dishes were transfected with 4 μg of Myc-PRMT6
plasmid along with 2 μg of Tat-FLAG wild-type or mutant
plasmids. Cells were harvested 24 h posttransfection with
phosphate-buffered saline containing 0.5 mM EDTA. The
cells were washed in phosphate-buffered saline and lysed
in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EDTA, protease inhibitor cocktail [Roche], 0.5% [wt/vol]
Triton X-100). The lysates were centrifuged at 1000 × g
to pellet debris, after which supernatants were collected.
Lysate total protein concentrations were determined by
the Bradford method [43] and, where applicable, ectopi-
cally expressed Renilla luciferase was quantified with the
BioLux Gaussia Luciferase Flex Assay Kit (New England
Biolabs). The lysates were boiled in Laemmli sample buffer
[44] and electrophoresed in a denaturating polyacry-
lamide gel (sodium dodecyl sulfate-polyacrylamide gel
electrophoresis [SDS-PAGE]) under reducing conditions.
Proteins were electroblotted to a polyvinylidene fluorideTable 2 Oligonucleotide sequences of inverse PCR primers us












aSequences are written 5′ to 3′.membrane (Millipore Corporation) using a semidry trans-
fer system (Bio-Rad Laboratories).
Tat-FLAG and its mutants were detected with rabbit
anti-DYKDDDDK antibody (Cell Signaling Technology).
Myc-PRMT6 and its mutants were detected with rabbit
anti-Myc-Tag clone 71D10 antibody (Cell Signaling). En-
dogenous PRMT6 was detected with rabbit anti-PRMT6
antibody (LifeSpan Biosciences). PRMT1 was detected with
rabbit anti-PRMT1 antibody (Epitomics). β-tubulin was
detected with mouse anti-β-tubulin clone 2-28-33 antibody
(Sigma-Aldrich), followed by horseradish peroxidase
(HRP)-conjugated goat anti-mouse antibody (Life Tech-
nologies Corporation). Rabbit antibodies were detected
with HRP-conjugated goat anti-rabbit antibody (Life Tech-
nologies). Bands were visualized with Super Signal West
Pico chemiluminescent substrate (Pierce Biotechnology).
Protein translation arrest
A549 cells growing in 6-cm dishes were transfected with
1 μg of Tat-FLAG plasmid either with or without 1 μg of
Myc-PRMT6 plasmid. Dishes were treated with 60 μg ·
ml-1 of cycloheximide (Sigma-Aldrich) at 24 h post-
transfection. Cells were harvested and lysed at 0, 1, 2, 4,
6 and 8 h post-treatment and lysates equivalent in total
protein amounts were assayed by western blot for Tat-
FLAG, Myc-PRMT6 and endogenous β-tubulin expres-
sion. Visualized bands were captured with an Image
Quant LAS 500 imager (GE Healthcare) and Tat-FLAG
band (pixel) intensities were quantified with ImageJ (ver-
sion 1.39). The protein half-life of Tat-FLAG was calcu-
lated using the formula described previously [13].
Quantitative RT-PCR
HeLa and A549 cells grown in 10-cm dishes were
washed with phosphate-buffered saline before their total
RNA were extracted with TRIzol reagent (Life Technolo-
gies) as per the manufacturer’s instructions. The totaled to construct Myc PRMT6 and Tat-FLAG mutants
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Superscript III MMLV RT (Life Technologies) according
to the manufacturer’s instructions. PRMT1, PRMT6 and
GAPDH transcripts in the cDNA were measured by quan-
titative PCR using Platinum SYBR Green qPCR supermix
(Life Technologies) on the Rotor-Gene Q (QIAGEN).
The primers used were primers f1 and r1 for PRMT1,
primers f2 and r2 for PRMT6, and primers GAPDH-f
and GAPDH-r for GADPH as described in [36]. Calcu-
lation of PRMT1 and PRMT6 relative expression ratios
followed the method of Pfaffl, where HeLa cells were
considered the “control”, A549 cells the “sample”, and
the GAPDH transcript as the “reference gene” as de-
fined therein [29].Transactivation assay
For the basal transcription assay, A549 cells growing in
24-well plate wells were cotransfected with 1 μg of pGL3-
LTR and 100 ng of pRL-SV40, with or without 50 ng or
250 ng of pMyc-PRMT6. For the Tat-mediated transacti-
vation assay, HeLa or A549 cells growing in 24-well plate
wells were cotransfected with 50 ng of pGL3-LTR, 50 ng
of pRL-SV40, and either 0 ng, 0.15 ng or 0.5 ng of
pcDNA3.1/Tat-FLAG, with or without 50 ng of pMyc-
PRMT6. Cells were harvested 24 h post-transfection using
Glo Lysis Buffer (Promega) as per the manufacturer’s in-
structions. Photinus luciferase was quantified with the
Steady-Glo Luciferase Assay System (Promega), and Renilla
luciferase was quantified with the BioLux Gaussia Lucifer-
ase Flex Assay Kit (New England Biolabs), as per the manu-
facturers’ instructions. Total protein concentrations in
lysates were quantified by the Bradford method [43].Virus production, infection and flow cytometry
A549 cells in 10-cm dishes were transfected with 5 μg of
pGCH/EGFP, 2.5 μg of pCMV/VSV-G and 2.5 μg of either
pcDNA3.1 (“empty vector”), pMyc-PRMT6 or pMyc-
PRMT6 mut. Virus particles in the culture media were
collected 48 h post-transfection and quantified for viral
capsid levels by ELISA (Zeptometrix Corporation). HeLa
cells growing in 6-well plates at 2 × 105 cells per well were
infected with 20 ng per well (capsid equivalent) of virus in
the presence of 8 μg · ml-1 hexadimethrine bromide.
Cells were harvested 42 h post-infection with phosphate-
buffered saline containing 0.5 mM EDTA (EDTA/PBS) be-
fore being fixed with 0.5% [wt/vol] formaldehyde for
5 min. Cells were washed and resuspended in EDTA/PBS
in order to analyze EGFP expression with a LSR Fortessa
flow cytometer (Becton, Dickinson and Company). Cells
were gated on side-scatter and forward-scatter parameters
and excited for fluorescence with the 488 nm and 561 nm
light sources.Statistical analyses
Hartley’s test was used to determine homoscedasticity
(equivalence of variance) between data sets. Student’s t
test was used to evaluate null hypotheses for homoscedas-
tic data, while Welch’s t test was used for heteroscedastic
data. Rejection of null hypotheses occurred when p < 0.05.
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